* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Friday, October 10, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    The Best “Friends” Halloween Episodes That Blend Spooky And Silly In The Perfect Way – Yahoo

    The Best “Friends” Halloween Episodes That Blend Spooky And Silly In The Perfect Way – Yahoo

    MSG Entertainment Takes Radio City Music Hall Into the Future With Introduction of Sphere Immersive Sound – Business Wire

    MSG Entertainment Transforms Radio City Music Hall with Cutting-Edge Sphere Immersive Sound Experience

    Israel’s Entertainment Industry Is Being Targeted by the Left in Hollywood and the Right at Home – The Wall Street Journal

    Inside the Fierce Clash Shaping Israel’s Entertainment Industry: Hollywood vs. Local Voices

    Offset Is Ready To Finalize Divorce With Cardi B for a Major Reason – Yahoo

    Offset Poised to Finalize Divorce from Cardi B for a Major Reason

    Beyond the Stage: 8 Performing Arts Centers Driving Entertainment and Education – Livability.com

    Beyond the Stage: 8 Performing Arts Centers Transforming Entertainment and Education

    Row K Entertainment Emerges as Major New Hollywood Buyer With Splashy TIFF Shopping Spree – TheWrap

    Row K Entertainment Emerges as Major New Hollywood Buyer With Splashy TIFF Shopping Spree – TheWrap

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    4J schools trying out new electronic hall pass technology – Lookout Eugene-Springfield

    4J Schools Unveils Cutting-Edge Electronic Hall Pass System to Transform Student Experience

    China outlines more controls on exports of rare earths and technology – fox40.com

    China Unveils Tougher Restrictions on Rare Earth and Technology Exports

    Wisconsin Dairy Leads the Way with Cutting-Edge Technology Systems

    ENERCON and Biome collaborate for wind turbine noise reduction technology – Yahoo Finance

    ENERCON and Biome Join Forces to Revolutionize Wind Turbine Noise Reduction

    US and investors gambling on unproven nuclear technology, warn experts – Financial Times

    US and investors gambling on unproven nuclear technology, warn experts – Financial Times

    Is Light-Speed Analog Computing the Future of Technology? – BIOENGINEER.ORG

    Could Light-Speed Analog Computing Transform the Future of Technology?

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    The Best “Friends” Halloween Episodes That Blend Spooky And Silly In The Perfect Way – Yahoo

    The Best “Friends” Halloween Episodes That Blend Spooky And Silly In The Perfect Way – Yahoo

    MSG Entertainment Takes Radio City Music Hall Into the Future With Introduction of Sphere Immersive Sound – Business Wire

    MSG Entertainment Transforms Radio City Music Hall with Cutting-Edge Sphere Immersive Sound Experience

    Israel’s Entertainment Industry Is Being Targeted by the Left in Hollywood and the Right at Home – The Wall Street Journal

    Inside the Fierce Clash Shaping Israel’s Entertainment Industry: Hollywood vs. Local Voices

    Offset Is Ready To Finalize Divorce With Cardi B for a Major Reason – Yahoo

    Offset Poised to Finalize Divorce from Cardi B for a Major Reason

    Beyond the Stage: 8 Performing Arts Centers Driving Entertainment and Education – Livability.com

    Beyond the Stage: 8 Performing Arts Centers Transforming Entertainment and Education

    Row K Entertainment Emerges as Major New Hollywood Buyer With Splashy TIFF Shopping Spree – TheWrap

    Row K Entertainment Emerges as Major New Hollywood Buyer With Splashy TIFF Shopping Spree – TheWrap

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    4J schools trying out new electronic hall pass technology – Lookout Eugene-Springfield

    4J Schools Unveils Cutting-Edge Electronic Hall Pass System to Transform Student Experience

    China outlines more controls on exports of rare earths and technology – fox40.com

    China Unveils Tougher Restrictions on Rare Earth and Technology Exports

    Wisconsin Dairy Leads the Way with Cutting-Edge Technology Systems

    ENERCON and Biome collaborate for wind turbine noise reduction technology – Yahoo Finance

    ENERCON and Biome Join Forces to Revolutionize Wind Turbine Noise Reduction

    US and investors gambling on unproven nuclear technology, warn experts – Financial Times

    US and investors gambling on unproven nuclear technology, warn experts – Financial Times

    Is Light-Speed Analog Computing the Future of Technology? – BIOENGINEER.ORG

    Could Light-Speed Analog Computing Transform the Future of Technology?

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer

January 4, 2024
in Health
Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer
Share on FacebookShare on Twitter

A novel drug combination led to clinically meaningful antitumor activity in metastatic ESR1-mutated, estrogen receptor-positive (ER+)/HER2-negative breast cancer that had progressed on CDK4/6 inhibition, a small prospective study showed.

Adding the selective estrogen receptor modulator (SERM) lasofoxifene to abemaciclib (Verzenio) resulted in a median progression-free survival (PFS) of 56 weeks, and a 24-week clinical benefit rate (CBR) of 65.5%. The combination was well tolerated with no new or unexpected toxicities and low rates of grade ≥3 toxicity.

The findings supported the initiation of a phase III randomized trial of the combination, reported Senthil Damodaran, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston, and co-authors in Annals of Oncology.

“All patients in ELAINE 2 had baseline ESR1 mutations, which are associated with a less favorable prognosis,” the authors pointed out during their discussion of the results. “Two of the four patients who developed rapid disease progression after 3-4 months on prior abemaciclib-based treatment experienced durable clinical benefit with lasofoxifene plus abemaciclib in ELAINE 2, suggesting that lasofoxifene contributes substantially to PFS outcomes and may synergistically interact with abemaciclib in modulating ER- and CDK-signaling cross-talk.”

A second study reported in the same issue of the journal showed no statistically significant clinical benefits with lasofoxifene versus the selective estrogen receptor degrader (SERD) fulvestrant in metastatic ESR1-mutated, ER+/HER2- breast cancer, but all clinical endpoints favored lasofoxifene, reported Matthew Goetz, MD, of the Mayo Clinic in Rochester, Minnesota, and co-authors.

In both studies, investigators examined dynamic changes in ESR1 allelic fraction during lasofoxifene treatment, which revealed significant reductions in mutant allelic fraction for several variants, noted the author of an accompanying editorial.

“Lasofoxifene demonstrated impressive target engagement across a wide spectrum of ESR1 variants,” wrote Seth Wander, MD, Massachusetts General Hospital and Harvard Medical School in Boston. “Emerging evidence supports the unsurprising notion that different ESR1 mutations convey distinct impacts on disease progression and therapeutic resistance.”

Ongoing studies “will foster new opportunities and new questions,” Wander continued. “Will there be a role for these agents as monotherapy, or will we continue to rely on combinations with other targeted agents? And which partner will provoke optimal benefit with these novel antiestrogens … As we develop these therapeutic strategies, we must remain focused on expanding our understanding of the molecular pathways driving progression in each individual patient.”

The open-label, multicenter, phase II ELAINE 2 trial reflected the evolving understanding of ESR1 mutations’ effect on ER+ breast cancer, including endocrine resistance, metastasis, and poor outcomes, Damodaran and co-authors noted in their introduction. Current systemic options for ESR1-mutated, HR+/HER2- metastatic breast cancer post-CDK4/6 inhibition are limited, and no established standard has emerged.

Recent small studies have shown modest clinical benefit from combined treatment with a CDK4/6 inhibitor and a SERD for ESR1-mutated advanced HR+ breast cancer after progression on CDK4/6 inhibition, underscoring the need for new and novel approaches, the authors continued. Lasofoxifene reduced the incidence of invasive ER+ breast cancer in a randomized trial in osteoporosis. Additionally, lasofoxifene demonstrated superior antitumor activity versus fulvestrant in a preclinical model of ESR1-mutated metastatic breast cancer, either alone or in combination with palbociclib (Ibrance).

Following the “encouraging antitumor activity” of lasofoxifene in the ELAINE 1 trial reported by Goetz and colleagues, ELAINE 2 was initiated to evaluate lasofoxifene’s safety and efficacy in combination with abemaciclib in metastatic ER+/HER2- breast cancer associated with ESR1 mutations.

ELAINE 2 included 29 patients, all with metastatic HR+/HER2- breast cancer and acquired ESR1 mutations. All the patients had disease that had progressed on prior systemic therapy, including CDK4/6 inhibition in 28 of 29 cases. Treatment consisted of lasofoxifene plus abemaciclib (regardless of the prior CDK4/6 inhibitor, which included abemaciclib in four cases).

Treatment continued until disease progression or development of unacceptable toxicity. The primary endpoint was safety/tolerability of the combination, and PFS was a secondary endpoint. The most common all-grade treatment emergent adverse events (TEAEs) included diarrhea (82.8%), nausea (51.7%), fatigue (37.9%), vomiting (31.0%), anemia (27.6%), dyspnea (27.6%), decreased white blood cell count (27.6%), and increased blood creatinine (24.1%).

Two patients developed grade 4 neutropenia. The most common grade 3 TEAEs were anemia (10.3%), hypokalemia (10.3%), neutropenia (6.9%), and fall (6.9%). No patient died during the study. One patient discontinued because of grade 2 diarrhea.

In addition to the median PFS exceeding 1 year, 6-month PFS was 76.1%, 12-month PFS was 56.1%, and 18-month PFS was 38.8%. The objective response rate was 55.6% among 18 patients with measurable lesions. ESR1-mutant circulating tumor DNA allele fraction decreased in 21 of 26 evaluable patients from baseline to week 4.

The ELAINE 1 trial included 103 patients with metastatic ESR1-mutated metastatic HR+/HER2- breast cancer. The patients were randomized to lasofoxifene or fulvestrant, and the primary endpoint was PFS.

Patients assigned to lasofoxifene had a median PFS of 24.2 weeks versus 16.2 weeks for the fulvestrant arm (P=0.138). CBR (36.5% vs 21.6%), objective response (13.2% vs 2.9%), 6-month PFS (53.4% vs 37.9%), and 12-month PFS (30.7% vs 14.1%) all favored lasofoxifene, but none of the differences achieved statistical significance, Goetz and co-authors reported.

author['full_name']

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Disclosures

The ELAINE trials were supported by Sermonix Pharmaceuticals.

Damodaran disclosed relationships with EMD Serono, Guardant Health, Taiho Pharmaceuticals, Novartis, and Sermonix Pharmaceuticals. Co-authors disclosed multiple relationships with industry.

Wander disclosed relationships with Foundation Medicine, Veracyte, Eli Lilly, Pfizer, Puma Biotechnology, Novartis, Biovica, AstraZeneca, 2ndMD, Genentech, Nuvation Bio, Regor Therapeutics, and Sermonix Pharmaceuticals.

Primary Source

Annals of Oncology

Source Reference: Damodaran S, et al “Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2” Ann Oncol 2023; DOI: 10.1016/j.annonc.2023.09.3104.

Secondary Source

Annals of Oncology

Source Reference: Goetz MP, et al “Lasofoxifene versus fulvestrant for ERD/HER2L metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial” Ann Oncol 2023; DOI: 10.1016/j.annonc.2023.09.3103.

Additional Source

Annals of Oncology

Source Reference: Wander SA “The ELAINE trials and the future of personalized therapy for hormone receptor-positive metastatic breast cancer” Ann Oncol 2023; DOI: 10.1016/j.annonc.2023.10.792.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/hematologyoncology/breastcancer/108115

Tags: Combinationhealthshows
Previous Post

Opening Blood-Brain Barrier to Deliver Alzheimer’s Drug Shows Promise

Next Post

Trial: Cleaner Cookstove Fuel Not Enough to Improve Infant Health

Salesians in Kenya Set to Roll Out Comprehensive Integral Ecology Plan to End “piecemeal” Approach – aciafrica.org

Salesians in Kenya Launch Bold New Plan to End Fragmented Approach to Integral Ecology

October 10, 2025
From refugee to Nobel: Yaghi hails science’s ‘equalising force’ – The Hindu

From refugee to Nobel: Yaghi hails science’s ‘equalising force’ – The Hindu

October 10, 2025
The “Silent Killer” Doesn’t Have to Be Silent: How Laboratory Science Is Changing the Story – Dark Daily

The “Silent Killer” Speaks Up: How Laboratory Science Is Transforming the Narrative

October 10, 2025
Mbappe credits Madrid lifestyle for helping him reset mentally and physically – Reuters

Mbappe credits Madrid lifestyle for helping him reset mentally and physically – Reuters

October 10, 2025
4J schools trying out new electronic hall pass technology – Lookout Eugene-Springfield

4J Schools Unveils Cutting-Edge Electronic Hall Pass System to Transform Student Experience

October 10, 2025
Six Pack of college football picks, predictions: Alabama vs. Missouri, Oregon vs. Indiana in spotlight – CBS Sports

Six Can’t-Miss College Football Showdowns: Alabama vs. Missouri and Oregon vs. Indiana Steal the Spotlight

October 10, 2025

High Five: The rest of the world’s top upcoming qualifiers – The New York Times

October 10, 2025
Donald Trump’s fortress economy is starting to hurt America – The Economist

How Donald Trump’s Fortress Economy Is Starting to Hurt America

October 10, 2025
The Best “Friends” Halloween Episodes That Blend Spooky And Silly In The Perfect Way – Yahoo

The Best “Friends” Halloween Episodes That Blend Spooky And Silly In The Perfect Way – Yahoo

October 10, 2025
Board of Health Meeting – City of Somerville (.gov)

Inside the Latest Somerville Board of Health Meeting: Key Updates and Decisions

October 10, 2025

Categories

Archives

October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
« Sep    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (861)
  • Economy (881)
  • Entertainment (21,754)
  • General (17,517)
  • Health (9,923)
  • Lifestyle (894)
  • News (22,149)
  • People (882)
  • Politics (891)
  • Science (16,092)
  • Sports (21,382)
  • Technology (15,862)
  • World (864)

Recent News

Salesians in Kenya Set to Roll Out Comprehensive Integral Ecology Plan to End “piecemeal” Approach – aciafrica.org

Salesians in Kenya Launch Bold New Plan to End Fragmented Approach to Integral Ecology

October 10, 2025
From refugee to Nobel: Yaghi hails science’s ‘equalising force’ – The Hindu

From refugee to Nobel: Yaghi hails science’s ‘equalising force’ – The Hindu

October 10, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version